A Correlative Imaging Study of in vivo and ex vivo Biodistribution of Solid Lipid Nanoparticles.
Animals
Biological Availability
Fluorescent Dyes
/ chemistry
Indocyanine Green
/ chemistry
Lipids
/ chemistry
Liver
/ drug effects
Male
Mice, Nude
Microscopy, Electron, Transmission
Microscopy, Fluorescence
Multimodal Imaging
/ methods
Nanoparticles
/ analysis
Rhodamines
/ chemistry
Tissue Distribution
light microscopy
lipid-based nanoparticles
optical imaging
systemic biodistribution
tissue accumulation
transmission electron microscopy
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
accepted:
07
02
2020
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Solid lipid nanoparticles are largely used in biomedical research and are characterized by high stability and biocompatibility and are also able to improve the stability of various loaded molecules. In vitro studies demonstrated that these nanoparticles are low cytotoxic, while in vivo studies proved their efficiency as nanocarriers for molecules characterized by a low bioavailability. However, to our knowledge, no data on the systemic biodistribution and organ accumulation of solid lipid nanoparticles in itself are presently available. In this view, we investigated the solid lipid nanoparticles biodistribution by a multimodal imaging approach correlating in vivo and ex vivo analyses. We loaded solid lipid nanoparticles with two different fluorophores (cardiogreen and rhodamine) to observe them with an optical imager in the whole organism and in the excised organs, and with fluorescence microscopy in tissue sections. Light and transmission electron microscopy analyses were also performed to evaluate possible structural modification or damage due to nanoparticle administration. Solid lipid nanoparticles loaded with the two fluorochromes showed good optic characteristics and stable polydispersity. After in vivo administration, they were clearly detectable in the organism. Four hours after the injection, the fluorescent signal occurred in anatomical districts corresponding to the liver and this was confirmed by the ex vivo acquisitions of excised organs. Brightfield, fluorescence and transmission electron microscopy confirmed solid lipid nanoparticles accumulation in hepatocytes without structural damage. Our results support the systemic biocompatibility of solid lipid nanoparticles and demonstrate their detailed biodistribution from the whole organism to organs until the cells.
Identifiants
pubmed: 32214808
doi: 10.2147/IJN.S236968
pii: 236968
pmc: PMC7078788
doi:
Substances chimiques
Fluorescent Dyes
0
Lipids
0
Rhodamines
0
Indocyanine Green
IX6J1063HV
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1745-1758Informations de copyright
© 2020 Mannucci et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Control Release. 2017 Oct 28;264:306-332
pubmed: 28844756
Curr Drug Deliv. 2008 Oct;5(4):324-31
pubmed: 18855604
Biomed Mater Eng. 2005;15(5):393-402
pubmed: 16179760
Eur J Pharm Biopharm. 2000 Jul;50(1):161-77
pubmed: 10840199
Colloids Surf B Biointerfaces. 2020 Apr;188:110749
pubmed: 31927466
Nanomedicine. 2017 Feb;13(2):693-700
pubmed: 27720928
Clin Liver Dis (Hoboken). 2013 Mar 29;2(Suppl 1):S4-S7
pubmed: 30992875
Expert Opin Drug Deliv. 2012 May;9(5):497-508
pubmed: 22439808
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96
pubmed: 11311991
Int J Biochem Cell Biol. 2017 Dec;93:62-73
pubmed: 29111382
Small. 2010 Jan;6(1):12-21
pubmed: 19844908
Eur J Pharm Biopharm. 2014 May;87(1):1-18
pubmed: 24530885
Exp Biol Med (Maywood). 2017 Oct;242(16):1605-1616
pubmed: 28467181
Pharm Dev Technol. 2019 Dec;24(10):1299-1307
pubmed: 31507245
Int J Pharm. 2014 Oct 20;474(1-2):6-13
pubmed: 25102112
Small. 2008 Jan;4(1):26-49
pubmed: 18165959
Expert Opin Drug Deliv. 2016 Aug;13(8):1121-31
pubmed: 27073977
Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
pubmed: 20402623
Cell Mol Life Sci. 2018 Sep;75(18):3313-3327
pubmed: 29936596
J Microsc. 2013 Oct;252(1):8-15
pubmed: 23841905
Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:982-994
pubmed: 27524099
Int J Pharm. 2008 Jan 4;346(1-2):124-32
pubmed: 17651933
Colloids Surf B Biointerfaces. 2016 Mar 1;139:52-61
pubmed: 26700233
J Gastroenterol. 2019 Mar;54(3):218-225
pubmed: 30643981
J Control Release. 2012 Aug 10;161(3):927-32
pubmed: 22580111
Int J Nanomedicine. 2007;2(3):289-300
pubmed: 18019829
Eur J Pharm Biopharm. 2016 Dec;109:184-193
pubmed: 27789356
Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72
pubmed: 15109768
Eur J Pharm Biopharm. 2009 Feb;71(2):161-72
pubmed: 18824097
AAPS PharmSciTech. 2018 May;19(4):1712-1719
pubmed: 29532427
Hepatology. 1999 Dec;30(6):1339-46
pubmed: 10573509
J Control Release. 2012 Oct 10;163(1):34-45
pubmed: 22698939
Crit Rev Ther Drug Carrier Syst. 2017;34(3):257-282
pubmed: 28845761
J Control Release. 2019 Feb 10;295:187-200
pubmed: 30610952
ISRN Biochem. 2013 May 21;2013:238428
pubmed: 25937958
Eur J Pharm Biopharm. 2017 Jun;115:285-296
pubmed: 28412473
Biomed Pharmacother. 2018 Jul;103:598-613
pubmed: 29677547
Nanoscale. 2018 Sep 20;10(36):16962-16983
pubmed: 30182106
Eur J Histochem. 2016 Apr 14;60(2):2640
pubmed: 27349319
J Control Release. 2012 Jul 20;161(2):403-8
pubmed: 22306428
Phys Med Biol. 2009 Dec 7;54(23):L57-62
pubmed: 19920307
Pharm Res. 2008 Jul;25(7):1521-30
pubmed: 18172580
Eur J Pharm Biopharm. 2016 Nov;108:235-252
pubmed: 27519829
Eur J Pharm Biopharm. 2014 Aug;87(3):433-44
pubmed: 24833004
Colloids Surf B Biointerfaces. 2018 Jan 1;161:302-313
pubmed: 29096375
Biomaterials. 2004 Jul;25(15):3065-71
pubmed: 14967540
Nanomaterials (Basel). 2017 May 27;7(6):
pubmed: 28554993
Adv Exp Med Biol. 2017;960:443-467
pubmed: 28585211